US Skin Care Actives Formulation Patents Granted in 2013
US PATENTS IN ACTIVES FOR SKIN CARE GRANTED IN  2013
This list includes patents granted in the United States. The list was retrieved by searching the claims section of all patent applications published. Salient search terms include skin care
active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening, blemish removal, etc. This category includes technology
related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavengers, "green" derived molecules and compounds having unique
sensory properties.
Clck to enlarge and view details
   
US Patents Granted in 2012
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENTS IN SKIN CARE ACTIVES GRANTED IN 2013



Patent No.: US8349793B2  Issued: 08/Jan/2013

Title: METHOD FOR TREATMENT OF INFLAMMATORY DISEASE AND DISORDER

Applicant/Assignee: HEAL0R, LTD

Application No.: 13/181687   Filing Date: 13/Jul/2011

Abstract:

The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta.

Priority: WO2011IL00032 Applic. Date: 2011-01-11; US2010-293794P Applic. Date: 2010-01-11; US2010-405509P Applic. Date: 2010-10-21

Inventor: BRAIMAN-WIKSMAN LIORA [IL]; TENNENBAUM TAMAR [IL]; SAGIV YUVAI [IL]; GARTSBEIN MARINA [IL]; BRENER EPHRAIM [IL]; BEN-HAMO MOSHE [IL]; HAMMER LIAT [IL]


Patent No.: US8357392B2  Issued: 22/Jan/2013

Title: Dry antiseptic wipes comprising an amphoteric surfactant

Applicant/Assignee:

Application No.: 13/297343   Filing Date: 16/Nov/2011

Abstract:

A personal skin cleansing wipe comprising a flexible substantially dry matrix formed from synthetic, woven, non-woven or knitted fibers impregnated with a substantially anhydrous antimicrobial, antiseptic, antifungal solution in an amount wherein the matrix retains its substantially dry characteristics and the treatment solution includes an amount of PVP-iodine as active in solution in glycol and or glycerin. The treatment solution, in addition to an effective amount of PVP-iodine as active, contains surfactants, preferably Tego TM Betaine CK D, and optionally a compatible fragrance and/or moisturizer. The wipe is activated with water just prior to use.

Priority: US2010-803495 Applic. Date: 2010-06-30; US2009-589820 Applic. Date: 2009-10-30; US2005-118197 Applic. Date: 2005-05-02

Inventor: KELLY ALBERT R [US]; SAFERTEIN LOWELL [US]


Patent No.: US8357655B2  Issued: 22/Jan/2013

Title: Wound Healing Peptides and Methods of Use Thereof

Applicant/Assignee: TUFTS UNIVERSITY

Application No.: 12/811124   Filing Date: 08/Jan/2009

Abstract:

Methods and compositions for the treatment of wounds in a mammalian subject are provided. Particularly, novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation are provided.

Priority: US2008-010401P Applic. Date: 2008-01-08; WO2009US30463 Applic. Date: 2009-01-08

Inventor: HERMAN IRA M [US]


Patent No.: US8361485B2  Issued: 29/Jan/2013

Title: Conditioned cell culture medium compositions and methods of use

Applicant/Assignee: SKINMEDICA, INC

Application No.: 11/538380   Filing Date: 03/Oct/2006

Abstract:

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.

Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

Priority: US2002-979813 Applic. Date: 2002-07-19; WO2000US13016 Applic. Date: 2000-05-12; US1999-313538 Applic. Date: 1999-05-14

Inventor: NAUGHTON GAIL K [US]; HORWITZ DAVID L [US]; APPLEGATE MARK A [US]; ZELTINGER JOAN [US]; MANSBRIDGE JONATHAN N [US]; KERN ANDREAS [US]; LANDEEN LEE K [US]; RATCLIFFE ANTHONY [US]; PINNEY R EMMETT [US]


Patent No.: US8367606B2  Issued: 05/Feb/2013

Title: METHOD AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF DIABETIC AND AGED SKIN

Applicant/Assignee: HEALOR LTD

Application No.: 11/990583   Filing Date: 29/Aug/2006

Abstract:

Method and compositions are provided for treating or preventing a skin pathology or disorder associated with diabetes and/or aging, by topical administration of at least one agent capable of restoring an impaired physiological condition of the skin associated with said skin pathology or disorder. Examples of such agents include PKC modulating agents, various adipokines and insulin signaling related molecules. In particular, restoration of the subcutaneous adipose tissue can overcome many of the diabetic skin pathologies and aging skin disorders and conditions.

Priority: US2005-711666P Applic. Date: 2005-08-29; WO2006IL01001 Applic. Date: 2006-08-29

Inventor: TENNENBAUM TAMAR [IL]; BRAIMAN-WIKSMAN LIORA [IL]; SOLOMINIK INESSA [IL]; MEIR MICHAL [IL]


Patent No.: US8367609B2  Issued: 05/Feb/2013

Title: Methods of reducing skin damage and edema

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION

Application No.: 11/654776   Filing Date: 18/Jan/2007

Abstract:

This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of a subject.

Priority: US2006-760328P Applic. Date: 2006-01-18

Inventor: DETMAR MICHAEL [CH]; KAJIYA KENTARO [CH]


Patent No.: US8367619B2  Issued: 05/Feb/2013

Title: Methods for promoting elastogenesis and elastin fiber formation by increasing tropoelastin expression

Applicant/Assignee: BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON

Application No.: 12/526625   Filing Date: 07/Feb/2008

Abstract:

Compositions and methods are provided for promoting elastin fiber formation (elastogenesis) in a cell, including methods that comprise contacting a cell that is capable of elastogenesis with (i) a mutated biglycan polypeptide that lacks chondroitin sulphate proteoglycan chains, (ii) a versican V3 isoform polypeptide that lacks most or all of the polypeptide regions encoded by one or more of exons 4, 5 or 6 or by exons 9-10 or 11-13, and/or with (iii) metastatin.

Priority: US2007-901951P Applic. Date: 2007-02-16; WO2008US53341 Applic. Date: 2008-02-07

Inventor: WIGHT THOMAS N [US]; MERRILEES MERVYN [NZ]


Patent No.: US8377679B2  Issued: 19/Feb/2013

Title: Use of probiotic lactic acid bacteria for balancing the skin's immune system

Applicant/Assignee: NESTEC S.A

Application No.: 12/454722   Filing Date: 07/Aug/2009

Abstract:

The present invention pertains to the use of probiotics for the preparation of a carrier for balancing the skin's immune function. In particular, the present invention pertains to the use of probiotic micro-organisms for balancing the skin's immune function under stress conditions, such as a exposure to ultraviolet radiation, specifically for enhancing the skin's immune activity and reducing the tendency to develop allergic reactions under such conditions.

Priority: EP20000121865 Applic. Date: 2000-10-06; US2003-381911 Applic. Date: 2003-08-12; WO2001EP11475 Applic. Date: 2001-10-04

Inventor: BAUR MARKUS [DE]; BRETON LIONEL [FR]; COUZY FRANCOIS [CH]; GUENICHE AUDREY [FR]


Patent No.: US8383594B2  Issued: 26/Feb/2013

Title: Peptides Modified with Triterpenoids and Small Organic Molecules: Synthesis and use in Cosmeceuticals

Applicant/Assignee: SAMI LABS LIMITED

Application No.: 11/835165   Filing Date: 07/Aug/2007

Abstract:

The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency.

Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin. With added peptides which boost the collagen and other matrix protein, Triterpenoid peptides provide a complete protection against pre mature ageing and functions as a best anti ageing ingredient.

Priority:

Inventor: MAJEED MUHAMMED [US]; CHANDRAMOULI RENUKESHWAR H [IN]; NAGABHUSHANAM KALYANAM [US]; SOOD RATTAN [IN]; PRAKASH SUBBALAKSHMI [US]; ANAND SUSMITHA [IN]


Patent No.: US8389026B2  Issued: 05/Mar/2013

Title: Composition and Method for Skin Repair

Applicant/Assignee: ACCESS BUSINESS GROUP INTERNATIONAL LLC

Application No.: 12/872311   Filing Date: 31/Aug/2010

Abstract:

A composition and a method of using the composition is described that is effective to protect or repair oxidative damage to DNA in mammalian skin by up regulating each of SIRT1, Gadd45b, and SOD2. The composition includes at least two of a candle bush extract, noni leaf extract, and melon extract with each present in an amount such that the composition is effective to up regulate each of SIRT1, Gadd45b, and SOD2.

Priority: US2009-239240P Applic. Date: 2009-09-02

Inventor: BRUMBAUGH ERNEST H [US]; RAJGOPAL ARUN [US]


Patent No.: US8394362B2  Issued: 12/Mar/2013

Title: GEM DIFLUORINATED C-GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE FOR THE PRESERVATION OF BIOLOGICAL MATERIALS AND/OR IN CRYOSUGERY

Applicant/Assignee: INSTITUT NATIONAL DES SCIENCE APPLIQUEES DE ROUEN(INSA), INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA)

Application No.: 11/720670   Filing Date: 02/Dec/2005

Abstract:

The invention concerns a gem-difluorinated C-glycopeptide compound of formula (I) in which N is an integer between 1 and 5, R4=H, AA1, AA1-AA2 and R5=OH, AA1, AA1, AA2, with AA1, and AA2 are independents groups and represent amino acids with a non-functionalized side chain and R1, R2, R3 are independent groups and one of them is equal to formula (II), in which n is an integer between 3 and 4, Y, Y' are independent groups in which Y, Y'=H, OR, N3, NR'R'', SR''', where R=H, benzyl, trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, acetate group, R', R'''-H, alkyl, allyl, benzyl, tosylate group, C(-O)-alkyl, C(-O)-Bn, R'''=H, alkyl, acetate group, R6 is notably a group H, CH3, CH2OH, CH2-Glycoside group, CH2-OGP in which GP is a protector group such as an alkyl, benzyl, trimethylsilyl, tert-butyldimethylsilyl, tertbutyldiphenylsilyl, acetate group,

and R7=OH, OGP', NH2, N3, NHGP', NGP'GP'' in which GP' and GP'' is or not a protector group such as an alkyl, benzyl, trimethylsilyl, tertbutyldimethylsilyl, tert-butyldiphenylsilyl, acetate group, and RB is a hydrogen atom H or a free or protected alcohol function. It applies notably to preservation of biological materials and to cryosurgery.

Priority: FR20040012782 Applic. Date: 2004-12-02; WO2005IB03940 Applic. Date: 2005-12-02

Inventor: QUIRION JEAN-CHARLES [FR]; CASTELOT-DELIENCOURT-GODEFROY GERALDINE [FR]


Patent No.: US8398963B2  Issued: 19/Mar/2013

Title: Cosmetic agent

Applicant/Assignee: BASF SE

Application No.: 10/204346   Filing Date: 20/Aug/2002

Abstract:

The present invention relates to a cosmetic composition containing at least one water-soluble or water-dispersible polymer which has, in incorporated form, a) 5 to 50% by weight of an [alpha],[beta]-ethylenically unsaturated monomer of the formula I where R1 and X1 are defined herein, b) 25 to 90% by weight an N-vinylamide and/or N-vinyllactam, c) 0.5 to 30% by weight of a compound having a free-radically polymerizable, [alpha],[beta]-ethylenically unsaturated double bond and a cationogenic and/or cationic group per molecule, and d) 0 to 30% by weight of an [alpha],[beta]-ethylenically unsaturated monomer of the formula II where R3, X2, and R4 are defined herein, and the salts thereof.

Priority: DE2000108263 Applic. Date: 2000-02-23

Inventor: KIM SON NGUYEN [DE]; WOOD CLAUDIA [DE]


Patent No.: US8398997B2  Issued: 19/Mar/2013

Title: Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins

Applicant/Assignee: REVANCE THERAPEUTICS, INC

Application No.: 10/591732   Filing Date: 03/Mar/2005

Abstract:

A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or efficiency groups. The invention also relates to methods for reducing muscle paralysis and other conditions that may be treated with a botulinum toxin, particularly paralysis of subcutaneous, and most particularly, facial, muscles, by topically applying an effective amount of the botulinum toxin and carrier, in conjunction, to the subject's skin or epithelium. Kits for administration are also described.

Priority: US2004-550015P Applic. Date: 2004-03-03; WO2005US07524 Applic. Date: 2005-03-03

Inventor: DAKE MICHAEL D [US]; WAUGH JACOB M [US]


Patent No.: US8409596B2  Issued: 02/Apr/2013

Title: DEODORANT COMPOSITIONS

Applicant/Assignee: E. I. DU PONT DE NEMOURS AND COMPANY, E I DU PONT DE NEMOURS AND COMPANY

Application No.: 13/344237   Filing Date: 05/Jan/2012

Abstract:

This invention relates to deodorant compositions containing polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) in a variety of physical forms. In at least one embodiment, the polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) can be made from monomers (e.g., 1,3-propanediol) obtained from renewable resources, and can thus be more environmentally friendly than conventional deodorant compositions in terms of manufacture, use and disposal.

Priority: US2007-869056 Applic. Date: 2007-10-09

Inventor: SUNKARA HARI BABU [US]; POLADI RAJA HARI [US]


Patent No.: US8410055B2  Issued: 02/Apr/2013

Title: SKIN WOUND HEALING COMPOSITIONS AND METHODS OF USE THEREOF

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: 13/210200   Filing Date: 15/Aug/2011

Abstract:

A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90[alpha] or the middle domain plus the charged sequence of hsp90[alpha]. The composition is topically applied to skin wounds, covering the outer surface of the wound. The heat shock protein acts by promoting migration of both human epidermal keratinocyte and dermal fibroblasts to the wound in order to close, heal, and remodel the wound.

Priority: US2009-522446 Applic. Date: 2009-07-08; WO2008US50520 Applic. Date: 2008-01-08; US2007-879150P Applic. Date: 2007-01-08

Inventor: LI WEI [US]; CHEN MEI [US]; WOODLEY DAVID T [US]


Patent No.: US8414871B2  Issued: 09/Apr/2013

Title: CONTROLLED RELEASES OF ACTIVES IN SKIN

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 12/525529   Filing Date: 31/Jan/2008

Abstract:

Topical compositions are provided in which active compounds for topical delivery through the stratum corneum are complexed with nanospheres of a triblock copolymer having an A-B-A structure wherein each A end block is a water-soluble, hydrophilic and non-toxic polymer or oligomer

and the hydrophobic middle B block is a hydrophobic polymer or oligomer with the same or different repeating units having the structure according to formula:(I) wherein X is -C-R-C- or -C-

Z is between 2 and about 100, inclusive

R1 is CH-CH or (CH2), wherein n is from 0 to 18, inclusive

R2 is selected from hydrogen and straight and branched alkyl, alkoxy, alkylaryl and alkoxyaryl groups containing up to 18 carbon atoms

and R is selected from a bond or straight and branched alkyl, alkoxy, alkylaryl and alkoxyaryl groups containing up to 18 carbon atoms.

Priority: US2005-191181 Applic. Date: 2005-07-27; US2005-514215 Applic. Date: 2005-11-07; WO2003US15600 Applic. Date: 2003-05-15; US2007-887553P Applic. Date: 2007-01-31; US2002-378042P Applic. Date: 2002-05-15; WO2008US52728 Applic. Date: 2008-01-31

Inventor: KOHN JOACHIM [US]; MICHNIAK BOZENA [US]; DEVORE DAVID [US]; SHEIHET LARISA [US]; CHANDRA PRAFULLA [US]; BATHEJA PRIYA [US]


Patent No.: US8415289B2  Issued: 09/Apr/2013

Title: Bacterial-Derived BLIS for Treatment of Acne

Applicant/Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Application No.: 12/086335   Filing Date: 13/Dec/2006

Abstract:

This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bactericide or bacteriostat for acne-causing bacteria, namely P. acnes.

Priority: US2005-749633P Applic. Date: 2005-12-13; WO2006US47394 Applic. Date: 2006-12-13

Inventor: MARGOLIS DAVID [US]; BOWE WHITNEY [US]


Patent No.: US8420105B2  Issued: 16/Apr/2013

Title: Botulinum Toxin Administration to Treat Various Conditions

Applicant/Assignee: ALLERGAN, INC

Application No.: 13/212962   Filing Date: 18/Aug/2011

Abstract:

Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.

Priority: US2008-340150 Applic. Date: 2008-12-19; US2006-538503 Applic. Date: 2006-10-04; US2002-051952 Applic. Date: 2002-01-17; US2000-730237 Applic. Date: 2000-12-05

Inventor: WALKER PATRICIA S [US]


Patent No.: US8431127B2  Issued: 30/Apr/2013

Title: Method for treating pruritus comprising administering an NR10 antagonist

Applicant/Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA

Application No.: 12/746229   Filing Date: 05/Dec/2008

Abstract:

The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

Priority: JP20070315144 Applic. Date: 2007-12-05; WO2008JP72142 Applic. Date: 2008-12-05

Inventor: HIGUCHI YOSHINOBU [JP]; KASUTANI KEIKO [JP]; KITAMURA HIDETOMO [JP]; HASEGAWA MASAKAZU [JP]


Patent No.: US8431364B2  Issued: 30/Apr/2013

Title: BIOPOLYMER PRODUCED BY FERMENTING THE EXTRACT OF SOYBEAN WITH FOLIC ACID AND A COMPOSITION CONTAINING THEREOF

Applicant/Assignee: DAMY CHEMICAL CO., LTD, DAMY CHEMICAL CO. LTD

Application No.: 12/681725   Filing Date: 02/Oct/2008

Abstract:

Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition.

Priority: KR20070100311 Applic. Date: 2007-10-05; WO2008KR05816 Applic. Date: 2008-10-02

Inventor: CHO BOO SUN [KR]; KIM KWANG NYEON [KR]


Patent No.: US8435502B2  Issued: 07/May/2013

Title: COSMETIC/DERMATOLOGICAL COMPOSITIONS COMPRISING NAPHTHOIC ACID COMPOUNDS AND POLYURETHANE POLYMERS

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 13/171872   Filing Date: 29/Jun/2011

Abstract:

Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.

Priority: FR20050009493 Applic. Date: 2005-09-16; US2008-076169 Applic. Date: 2008-03-14; WO2006IB03852 Applic. Date: 2006-09-15; US2005-725279P Applic. Date: 2005-10-12

Inventor: MALLARD CLAIRE [FR]; FERRARA EVE [FR]


Patent No.: US8435548B2  Issued: 07/May/2013

Title: PEPTIDE DERIVATIVES AND COSMETIC COMPOSITION COMPRISING THE SAME

Applicant/Assignee: BIO-FD&C CO., LTD

Application No.: 12/646538   Filing Date: 23/Dec/2009

Abstract:

Disclosed are peptide derivatives, wherein glutathione-like peptides are connected to benzoic acid derivatives, and a cosmetic composition comprising the same. The peptide derivatives have excellent tyrosinase inhibition and anti-oxidative activities to show excellent skin whitening effect, biocompatibility without skin stimulation, and stability during long-term storage. Therefore, they can be effectively used for a cosmetic composition for skin whitening.

Priority: KR20090031705 Applic. Date: 2009-04-13

Inventor: JUNG DAI HYUN [KR]; MOH SANG HYUN [KR]; LEE JUNG HUN [KR]; KIM SU JUNG [KR]; KIM HYUNG SIK [KR]; SEO HYO HYUN [KR]; BAE YEON JA [KR]


Patent No.: US8435950B2  Issued: 07/May/2013

Title: Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same

Applicant/Assignee: ISP INVESTMENTS

Application No.: 13/143741   Filing Date: 07/Jan/2010

Abstract:

The present invention relates to peptide compounds of general formula (I) R1-X1-X2-Ser-Pro-Leu-Gln-X3-X4-R2. The present invention also relates, on the one hand, to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I) in a cosmetically or dermatologically acceptable medium, and on the other hand to its use in order to prevent or treat the cutaneous signs of aging and to protect the skin against the harmful effects caused by UV radiation. The invention lastly relates to a cosmetic treatment method for preventing and/or combatting cutaneous signs of aging and for protecting the skin against the harmful effects caused by UV radiation.

Priority: FR20090000069 Applic. Date: 2009-01-09; WO2010FR00007 Applic. Date: 2010-01-07

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]; IMBERT ISABELLE [FR]


Patent No.: US8440617B2  Issued: 14/May/2013

Title: HYPERBARIC TREATMENT IN WOUND HEALING

Applicant/Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Application No.: 12/532422   Filing Date: 21/Mar/2008

Abstract:

This invention relates to methods for treating chronic dermal ulcers using hyperbaric treatment in combination with progenitor cells and chemokine homing factors. Specifically, the invention relates to treatment of chronic wounds resulting from diabetes mellitus using compositions comprising EPC and SDF-1A, under hyperbaric condition to accelerate wound healing.

Priority: US2007-907147P Applic. Date: 2007-03-22; WO2008US03760 Applic. Date: 2008-03-21

Inventor: VELAZQUEZ OMAIDA C [US]; GALLAGHER KATHERINE A [US]


Patent No.: US8445439B2  Issued: 21/May/2013

Title: ITCH SUPPRESSANT

Applicant/Assignee: UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN

Application No.: 13/503153   Filing Date: 22/Oct/2010

Abstract:

The present invention provides an itch suppressant containing cholecystokinin 2 receptor agonist such as a peptide having an amino acid sequence homologous with a partial amino acid sequence of at least seven C-terminal amino acids of the peptide having the amino acid sequence represented by SEQ:ID No. 1 as an active ingredient as a rapid-acting itch suppressant effective in treating skin illnesses associated with strong itch such as atopic dermatitis having few side effects. [SEQ:IDNo.1] Val-Ser-Gln-Arg-Thr-Asp-Gly-Glu-Ser-Arg-Ala-His- Leu-Gly-Ala-Leu-Leu-Ala-Arg-Tyr-Ile-Gln-Gln-Ala- Arg-Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys- Asn-Leu-Gln-Asn-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser- Asp-Arg-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

Priority: JP20090244528 Applic. Date: 2009-10-23; WO2010JP68695 Applic. Date: 2010-10-22

Inventor: TOKURA YOSHIKI [JP]; FUKAMACHI SHOKO [JP]


Patent No.: US8450337B2  Issued: 28/May/2013

Title: Methods of Treating Skin Disorders with Caffeic Acid Analogs

Applicant/Assignee: MOLECULIN, LLC

Application No.: 12/570819   Filing Date: 30/Sep/2009

Abstract:

Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof.

The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.

Priority: US2008-101589P Applic. Date: 2008-09-30

Inventor: PRIEBE WALDEMAR [US]; CONRAD CHARLES [US]; MADDEN TIMOTHY [US]


Patent No.: US8454945B2  Issued: 04/Jun/2013

Title: TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY

Applicant/Assignee: PATHFINDER MANAGEMENT, INC, BERG PHARMA LLC

Application No.: 12/052825   Filing Date: 21/Mar/2008

Abstract:

The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.

Priority: US2007-919554P Applic. Date: 2007-03-22

Inventor: MCCOOK JOHN PATRICK [US]; PERSAUD INDUSHEKHAR [US]; NARAIN NIVEN RAJIN [US]


Patent No.: US8460713B2  Issued: 11/Jun/2013

Title: ADMINISTRATION OF CELLS AND CELLULAR EXTRACTS FOR REJUVENATION

Applicant/Assignee: REGENICS AS

Application No.: 13/267022   Filing Date: 06/Oct/2011

Abstract:

The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.

Priority: US2007-801778 Applic. Date: 2007-05-11; US2006-799560P Applic. Date: 2006-05-11

Inventor: GAMMELSAETER RUNHILD [NO]; REMMEREIT JAN [NO]


Patent No.: US8461108B2  Issued: 11/Jun/2013

Title: SUBDERMAL TISSUE REMODELING USING MYOSTATIN, METHODS AND RELATED SYSTEMS

Applicant/Assignee: MYOSCIENCE, INC

Application No.: 12/400698   Filing Date: 09/Mar/2009

Abstract:

Systems and methods of tissue remodeling or altering a surface of a skin of a patient are provided. A method includes increasing myostatin activity in a target tissue. Methods can include increasing myostatin activity in a target tissue in addition to various tissue remodeling techniques, including cryogenic cooling of target tissue for tissue remodeling.

Priority: US2008-034781P Applic. Date: 2008-03-07

Inventor: HSU MICHAEL [US]; ELKINS LISA [US]


Patent No.: US8470306B2  Issued: 25/Jun/2013

Title: CROSSLINKED POLYSILOXANES, A PROCESS FOR THEIR PREPARATION AND USE OF THE CROSSLINKED POLYSILOXANES IN EMULSIFIER SYSTEMS FOR WATER-IN-OIL EMULSIONS

Applicant/Assignee: EVONIK GOLDSCHMIDT GMBH

Application No.: 12/888603   Filing Date: 23/Sep/2010

Abstract:

The invention relates to crosslinked organopolysiloxanes which are linked by a polyether building block via the Si atoms, to emulsifier systems which have these crosslinked organopolysiloxanes, and also to cosmetic, dermatological or pharmaceutical formulations comprising a crosslinked organopolysiloxane or an emulsifier system comprising these.

Priority: US2009-245366P Applic. Date: 2009-09-24

Inventor: NEUMANN THOMAS [DE]; GRUENING BURGHARD [DE]; HOWE ANNA [US]; ADKINS DANA [US]; REDDINGER JERRY [US]


Patent No.: US8470774B2  Issued: 25/Jun/2013

Title: Deoxycorticosterone induced elastin production

Applicant/Assignee: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN

Application No.: 13/405744   Filing Date: 27/Feb/2012

Abstract:

Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.

Priority: US2008-157141 Applic. Date: 2008-06-06; US2007-942305P Applic. Date: 2007-06-06

Inventor: HINEK ALEKSANDER [CA]; MITTS THOMAS F [US]


Patent No.: US8470780B2  Issued: 25/Jun/2013

Title: METHODS AND COMPOSITIONS RELATED TO TARGETING WOUNDS, REGENERATING TISSUE, AND TUMORS

Applicant/Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE CALIFORNIA, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE

Application No.: 13/450972   Filing Date: 19/Apr/2012

Abstract:

Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.

Priority: US2007-951819 Applic. Date: 2007-12-06; US2006-868772P Applic. Date: 2006-12-06

Inventor: RUOSLAHTI ERKKI [US]; JAERVINEN TERO [US]


Patent No.: US8475815B2  Issued: 02/Jul/2013

Title: ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF

Applicant/Assignee:

Application No.: 12/741280   Filing Date: 29/Oct/2008

Abstract:

A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent comprising particles of the unsubstituted acrylate/substituted acrylate copolymer with a diameter of less than about 100mu. Methods for making a composition comprising an alloplastic injectable suspension for use as a dermal filler are provided. Methods of augmenting soft tissue to provide long-term reduction of a skin defect and the stimulation of collagen production are also provided.

Priority: US2007-926930 Applic. Date: 2007-10-29; WO2008US81608 Applic. Date: 2008-10-29

Inventor: BOUTROS AYMAN [US]


Patent No.: US8476231B2  Issued: 02/Jul/2013

Title: CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: SKINMEDICA. INC, ALLERGAN, INC

Application No.: 13/417017   Filing Date: 09/Mar/2012

Abstract:

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

Priority: US2009-349451 Applic. Date: 2009-01-06; US2006-538380 Applic. Date: 2006-10-03; US2002-979813 Applic. Date: 2002-07-19; WO2000US13016 Applic. Date: 2000-05-12; US1999-313538 Applic. Date: 1999-05-14

Inventor: NAUGHTON GAIL K [US]; HORWITZ DAVID L [US]; APPLEGATE MARK A [US]; ZELTINGER JOAN [US]; MANSBRIDGE JONATHAN N [US]; KERN ANDREAS [US]; LANDEEN LEE K [US]; RATCLIFFE ANTHONY [US]; PINNEY R EMMETT [US]


Patent No.: US8476235B2  Issued: 02/Jul/2013

Title: Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan

Applicant/Assignee: APOTEX TECHNOLOGIES INC

Application No.: 13/400317   Filing Date: 20/Feb/2012

Abstract:

A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is a stable pharmaceutical solid.

Priority: CA20062569204 Applic. Date: 2006-11-28; US2009-515217 Applic. Date: 2009-05-15; WO2007CA02123 Applic. Date: 2007-11-26

Inventor: TAM TIM FAT [CA]; N ZEMBA BLAISE [CA]; LEUNG-TOUNG REGIS [CA]; WANG YINGSHENG [CA]; ZHAO YANQING [CA]; YU LILY [CA]


Patent No.: US8476236B2  Issued: 02/Jul/2013

Title: TREATMENT OF SKIN CONDITIONS BY DICKKOPF1 (DKK1)

Applicant/Assignee: THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN S

Application No.: 13/492990   Filing Date: 11/Jun/2012

Abstract:

The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.

Priority: US2009-518052 Applic. Date: 2009-06-05; WO2007US86855 Applic. Date: 2007-12-07; US2006-873874P Applic. Date: 2006-12-07

Inventor: HEARING VINCENT [US]; YAMAGUCHI YUJI [JP]; PASSERON THIERRY [FR]


Patent No.: US8481089B2  Issued: 09/Jul/2013

Title: Topical Skin Care Formulations Comprising Plant Extracts

Applicant/Assignee: MARY KAY INC

Application No.: 13/323402   Filing Date: 12/Dec/2011

Abstract:

Disclosed are compositions and corresponding methods of their use that include extracts from a Lonicera maackii and Polygonum hydropiper. The composition can be used to reduce tyrosinase activity and elastase activity in skin cells.

Priority: US2010-869352 Applic. Date: 2010-08-26; US2009-237087P Applic. Date: 2009-08-26

Inventor: FLORENCE TIFFANY [US]; GAN DAVID [US]; HINES MICHELLE [US]


Patent No.: US8486454B2  Issued: 16/Jul/2013

Title: Method of attenuating neurogenic pain

Applicant/Assignee: FERRIS PHARMACEUTICALS, INC, SESSIONS PHARMACEUTICALS INC

Application No.: 11/540460   Filing Date: 29/Sep/2006

Abstract:

The present invention provides a method of attenuating the formation or reducing the severity of neurogenic pain in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic pain.

Priority: US2006-440550 Applic. Date: 2006-05-25; US2002-175119 Applic. Date: 2002-06-19; US2001-789275 Applic. Date: 2001-02-20; US1999-326836 Applic. Date: 1999-06-07; US1998-088424P Applic. Date: 1998-06-08

Inventor: SESSIONS ROBERT W [US]; KAHN ALAN R [US]


Patent No.: US8491881B2  Issued: 23/Jul/2013

Title: CONFORMABLE SOLVENT-BASED BANDAGE AND COATING MATERIAL

Applicant/Assignee: ROCHAL INDUSTRIES, LLP

Application No.: 13/460553   Filing Date: 30/Apr/2012

Abstract:

A biological coating material that includes a polymerizable polyacrylate monomer

a volatile liquid

a polymer selected from a synthetic rubber, a natural rubber, and a thermoplastic elastomer. The biological liquid coating material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin of a user inhibits the application surface from adhering to another surface.

Priority: US2009-414708 Applic. Date: 2009-03-31; US2006-465237 Applic. Date: 2006-08-17; US2005-708858P Applic. Date: 2005-08-17; US2005-708898P Applic. Date: 2005-08-17

Inventor: SALAMONE ANN BEAL [US]; SALAMONE JOSEPH C [US]


Patent No.: US8492366B2  Issued: 23/Jul/2013

Title: Enhancedly-solubilized beta-hydroxy acids and higher potency skin peels formulated therefrom

Applicant/Assignee: SOCIETE L'OREAL S.A

Application No.: 10/373102   Filing Date: 26/Feb/2003

Abstract:

The solubility in solvent media, notably alcoholic media, of the beta-hydroxy acids ("BHAs"), notably the chemical skin peeling agent salicylic acid, is markedly enhanced by solubilizing same in the presence of at least one alpha-hydroxy acid ("AHA")

higher potency, more concentrated BHA skin peel products are thus formulated.

Priority: US2002-416259P Applic. Date: 2002-10-07

Inventor: CORNELL MARC [US]; FARES HANI [US]; FOLTIS SIDNEY PETER [US]; HANSENNE ISABELLE [US]


Patent No.: US8497241B2  Issued: 30/Jul/2013

Title: WNT10-Derived Peptide and Use Thereof

Applicant/Assignee: CAREGEN CO., LTD

Application No.: 13/393370   Filing Date: 24/Nov/2009

Abstract:

The present invention relates to a WNT10-derived peptide, a composition for improving hair loss and skin conditions using the same, and a composition for treating a WNT10 signal transduction pathway-related disorder and DKK-1 protein-induced disorder the same. WNT10-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT10, and has much higher stability and skin penetration potency than natural-occurring WNT10. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT10 signal transduction pathway-related disorder and a DKK-1 protein-induced disorder.

In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.

Priority: KR20090081817 Applic. Date: 2009-09-01; WO2009KR06933 Applic. Date: 2009-11-24

Inventor: CHUNG YOUNG JI [KR]; KIM EUN MI [KR]; SONG SANG SU [KR]; CHO KYOUNG MI [KR]


Patent No.: US8507276B2  Issued: 13/Aug/2013

Title: Tissue culture media used as a component of cosmetics

Applicant/Assignee: JUVENA (INTERNATIONAL) AG,, LA PRAIRIE GROUP AG

Application No.: 11/285342   Filing Date: 23/Nov/2005

Abstract:

A cosmetic or dermatological preparation which comprises one or more tissue culture media, in particular one or more skin cell culture media.

Priority: DE2003123510 Applic. Date: 2003-05-24; DE2003155110 Applic. Date: 2003-11-24; DE20041020035 Applic. Date: 2004-04-22; WO2004EP05532 Applic. Date: 2004-05-22

Inventor: GOHLA SVEN [DE]; MOENKS MONIKA [CH]; IBANEZ SIBYLLE [CH]; EVANGELISTI CARMEN [CH]


Patent No.: US8507441B2  Issued: 13/Aug/2013

Title: USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS

Applicant/Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEMS OF HIGHER EDUCATION

Application No.: 13/503339   Filing Date: 22/Oct/2010

Abstract:

C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4

(2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4

or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions

wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4.

Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.

Priority: US2009-254143P Applic. Date: 2009-10-22; US2009-261280P Applic. Date: 2009-11-13; WO2010US53831 Applic. Date: 2010-10-22

Inventor: FEGHALI-BOSTWICK CAROL A [US]; YAMAGUCHI YUKIE [JP]


Patent No.: US8513185B2  Issued: 20/Aug/2013

Title: INHIBITION OF TREM RECEPTOR SIGNALING WITH PEPTIDE VARIANTS

Applicant/Assignee: SIGNABLOK, INC

Application No.: 13/501992   Filing Date: 13/Oct/2010

Abstract:

Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited.

The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

Priority: US2009-251283P Applic. Date: 2009-10-13; WO2010US52566 Applic. Date: 2010-10-13

Inventor: SIGALOV ALEXANDER B [US]


Patent No.: US8518424B2  Issued: 27/Aug/2013

Title: Resin Powder For Dermatologic Composition, Skin Cleansing Agent and Cosmetic Composition Using the Powder, and Preparation Processes of the Powder

Applicant/Assignee: FUJI XEROX CO., LTD

Application No.: 11/850034   Filing Date: 05/Sep/2007

Abstract:

Provided is a resin powder for a dermatologic composition composed of resin particles having an average volume particle size of 2.0 to 20.0 mum, a shape factor SF1 of 110 to 140 and an average volume particle size distribution GSDv of 1.3 or less. Also disclosed are a skin cleansing composition and a cosmetic composition containing the resin powder, and a preparation process of the resin powder.

Priority: JP20010248322 Applic. Date: 2001-08-17; US2001-015611 Applic. Date: 2001-12-17

Inventor: SASAKI YUKI [JP]; MATSUMURA YASUO [JP]; AOKI TAKAYOSHI [JP]; TOMINAGA ETSUO [JP]


Patent No.: US8518878B2  Issued: 27/Aug/2013

Title: Method for treating skin aging by administration of bFGF

Applicant/Assignee: LABO JUVERSA CO., LTD

Application No.: 13/233315   Filing Date: 15/Sep/2011

Abstract:

It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc.

Priority: JP20080085952 Applic. Date: 2008-03-28; US2010-934299 Applic. Date: 2010-09-24; WO2009JP01303 Applic. Date: 2009-03-24

Inventor: ONO ICHIRO [JP]


Patent No.: US8524210B2  Issued: 03/Sep/2013

Title: PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME

Applicant/Assignee: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN

Application No.: 12/781710   Filing Date: 17/May/2010

Abstract:

The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.

Priority: US2006-405843 Applic. Date: 2006-04-17; US2005-671557P Applic. Date: 2005-04-15; US2005-737586P Applic. Date: 2005-11-17

Inventor: JIMENEZ FELIPE [US]; MITTS THOMAS [US]; HINEK ALEKSANDER [CA]


Patent No.: US8529897B2  Issued: 10/Sep/2013

Title: INFLAMMATION-REGULATING COMPOSITIONS AND METHODS

Applicant/Assignee: CARNEGIE MELLON UNIVERSITY

Application No.: 12/673583   Filing Date: 15/Aug/2008

Abstract:

The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1beta, an anti-IL-6, an anti-TNF-alpha, and combinations thereof.

The polymer functions as a substrate or matrix for cell migration and tissue regeneration. The RGD peptide functions to promote cellular proliferation, migration and attachment to the polymer. The monoclonal antibody functions to inhibit the inflammatory response.

Priority: US2007-964933P Applic. Date: 2007-08-16; WO2008US73335 Applic. Date: 2008-08-15

Inventor: WASHBURN NEWELL [US]; BENCHERIF SIDI AHMED [US]; SUN LIANG TSO [US]


Patent No.: US8530406B2  Issued: 10/Sep/2013

Title: HMG-COA REDUCTASE DERIVED PEPTIDE AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/141123   Filing Date: 23/Dec/2009

Abstract:

The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2, derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Priority: FR20080007362 Applic. Date: 2008-12-23; WO2009FR01475 Applic. Date: 2009-12-23

Inventor: FARRA CLAUDE DAL [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Patent No.: US8535904B2  Issued: 17/Sep/2013

Title: METHOD OF ENHANCING SKIN BARRIER FUNCTION

Applicant/Assignee: POLA CHEMICAL INDUSTRIES INC

Application No.: 13/476868   Filing Date: 21/May/2012

Abstract:

A method for adjusting calcium ion in epidermis is described. The method involves applying a material for enhancing skin barrier function to the skin of a subject. Appropriate materials include Pimpinella extract, Asteroidea extract, L-Carnitine, Royal jelly hydrolysate, Pellicer, Palmaria extract, epsilon, gamma-Glutamyl lysine, Coptis japonica extract and citrus aurantium peel extract

Priority: JP20060331294 Applic. Date: 2006-12-08; JP20070133776 Applic. Date: 2007-05-21; US2009-516483 Applic. Date: 2009-05-27; WO2007JP74070 Applic. Date: 2007-12-07

Inventor: KURODA SHOHEI [JP]; YAMAMOTO TAKUYA [JP]; SAEKI YUKO [JP]; KURASAWA MASUMI [JP]


Patent No.: US8536135B2  Issued: 17/Sep/2013

Title: ADAPTIVE BIOCHEMICAL SIGNATURES

Applicant/Assignee: ONTHERIX, INC

Application No.: 13/035844   Filing Date: 25/Feb/2011

Abstract:

The present invention is related to methods of generating adaptive biochemical signatures in live cells and the use of said signatures to identify diagnostic and therapeutic modalities for human disease. The methods described herein comprise contacting a provocative agent to live cells and measuring and analyzing adaptive readouts. The methods of the invention may be used for therapeutic or diagnostic purposes.

Priority: US2010-933381 Applic. Date: 2010-12-13; WO2009US37695 Applic. Date: 2009-03-19; US2008-077575 Applic. Date: 2008-03-19; US2008-038013P Applic. Date: 2008-03-19; US2009-155091P Applic. Date: 2009-02-24

Inventor: MASCARENHAS DESMOND [US]


Patent No.: US8540976B2  Issued: 24/Sep/2013

Title: POLY (NON-CONJUGATED DIENE) BASED SUNSCREENS

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC

Application No.: 13/257775   Filing Date: 01/Apr/2010

Abstract:

A poly(non-conjugated diene) based sunscreen has a plurality of repeating units where each repeating unit has at least one UV absorbing chromophore that is situated between and connected by chains to two mono-ene units where each UV absorbing chromophore absorb UVA and UVB light. The poly(non-conjugated diene) based sunscreen can be included with a vehicle for application to the skin to prevent sunburn. The poly(non-conjugated diene) based sunscreen can be prepared by acyclic diene metathesis polymerization.

Priority: US2009-165764P Applic. Date: 2009-04-01; WO2010US29646 Applic. Date: 2010-04-01

Inventor: LEONARD JAMES KLEIN [US]; SLOAN KENNETH BERRY [US]; WAGENER KENNETH BOONE [US]


Patent No.: US8541361B2  Issued: 24/Sep/2013

Title: Composition

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: 13/264059   Filing Date: 23/Apr/2010

Abstract:

The present invention relates to compositions comprising a peptide with 2-12 amino acids substituted with a lipophilic moiety and a water soluble salt of an alkali, earth alkaline metal or transition metal. Furthermore, the invention relates to a container comprising such compositions. Additionally, the invention relates to the use of a water soluble salt of an alkali, earth alkaline metal or transition metal for reducing the adhesion of a peptide with 2-12 amino acids substituted with a lipophilic moiety to a surface.

Priority: EP20090158422 Applic. Date: 2009-04-22; US2009-202947P Applic. Date: 2009-04-22; WO2010IB01011 Applic. Date: 2010-04-23

Inventor: HEIDL MARC [DE]; WILLE ROMAN [CH]; ZIEGLER HUGO [CH]


Patent No.: US8545821B2  Issued: 01/Oct/2013

Title: Cosmetic Use of Water-Redispersible Powders

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/899873   Filing Date: 07/Oct/2010

Abstract:

Cosmetic compositions comprising water-redispersible polymers are provided, as well as methods for using such compositions in cosmetics that afford powder-to-liquid and moisture-resistant benefits. These cosmetics can provide easier portability, as well as long wear benefits when topically applied to the skin or hair.

Priority: US2009-258251P Applic. Date: 2009-11-05

Inventor: MAITRA PRITHWIRAJ [US]; CHAN WENDY [US]


Patent No.: US8545851B2  Issued: 01/Oct/2013

Title: COMPOSITION FOR IMPROVING INFLAMMATORY DISEASE USING ABH ANTIGENS

Applicant/Assignee: SNU R&DB FOUNDATION

Application No.: 13/143462   Filing Date: 07/Jan/2010

Abstract:

The present invention relates to a composition for improving inflammatory disease, and more specifically to a composition for improving inflammatory disease able to improve inflammatory reactions and the barrier function of epithelial tissue such as the skin, to enhance aging resistance and skin elasticity and to prevent or treat aging.

The present invention makes it possible to control inflammatory reactions by modulating the expression and modulating the activity of ABH antigens, and thus the composition of the present invention can be employed as a development marker for therapeutic agents designed to soothe or treat or help in the treatment of disease caused by inflammatory reaction in body tissue and notably the skin expressed by ABH antigens, and can be used in the development of external preparations and cosmetics containing external preparations designed for the purposes such as restoration of normal function and moisturization, wrinkle enhancement, whitening and elasticity recovery in skin through modulation of differentiation of keratinocytes and the skin barrier function.

Priority: KR20090002078 Applic. Date: 2009-01-09; WO2010KR00103 Applic. Date: 2010-01-07

Inventor: OH JANG HEE [KR]; JUNG JI-YONG [KR]; LEE DONG HUN [KR]; LEE SERAH [KR]; KIM YEON KYUNG [KR]; SHIN JEONG-EUN [KR]; LEE JUNE HYUNKYUNG [KR]; CHUNG JIN HO [KR]


Patent No.: US8546340B2  Issued: 01/Oct/2013

Title: SOOTHING PHARMACEUTICAL OR COSMETIC COMPOSITION COMPRISING A PEPTIDE THAT ACTIVATES HMG-COA REDUCTASE

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/141392   Filing Date: 23/Dec/2009

Abstract:

A soothing cosmetic or pharmaceutical composition that includes at least one peptide that activates human HMG-CoA reductase general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AAp-R2 in a physiologically suitable medium is disclosed. The invention further applies to a cosmetic treatment method intended to combat skin irritations. Additionally, methods of treating skin irritations with such a composition are described.

Priority: FR20080007365 Applic. Date: 2008-12-23; WO2009FR01477 Applic. Date: 2009-12-23

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Patent No.: US8551459B2  Issued: 08/Oct/2013

Title: COMPOSITION COMPRISING A POLYOL AND A OIL-SOLUBLE HIGH CARBON POLAR MODIFIED POLYMER

Applicant/Assignee: L'OREAL S.A, L'OREAL

Application No.: 12/825600   Filing Date: 29/Jun/2010

Abstract:

The invention relates to a composition comprising an oil-soluble high carbon polar modified polymer and a hyperbranched polyol.

Priority: US2009-221278P Applic. Date: 2009-06-29; US2009-221292P Applic. Date: 2009-06-29

Inventor: BUI HY SI [US]; KANJI MOHAMED [US]; TONG ANITA CHON [US]; HALPERN SUSAN [US]


Patent No.: US8551465B2  Issued: 08/Oct/2013

Title: COMPOSITION COMPRISING A POLYOL AND A OIL-SOLUBLE POLAR MODIFIED POLYMER

Applicant/Assignee: L'OREAL S.A, L' OREAL

Application No.: 12/825816   Filing Date: 29/Jun/2010

Abstract:

The invention relates to a composition comprising a oil-soluble polar modified polymer and a hyperbranched polyol.

Priority: US2009-221400P Applic. Date: 2009-06-29; US2009-221326P Applic. Date: 2009-06-29; US2009-221289P Applic. Date: 2009-06-29

Inventor: BUI HY SI [US]; KANJI MOHAMED [US]; TONG ANITA CHON [US]; LI CHUNHUA [US]; HALPERN SUSAN [US]; BAVOUZET BRUNO [US]; KAWARATANI YORIKO [US]


Patent No.: US8557230B2  Issued: 15/Oct/2013

Title: Cosmetic compositions containing block copolymers, tackifiers and shine enhancing agents

Applicant/Assignee: L'OREAL

Application No.: 11/417977   Filing Date: 03/May/2006

Abstract:

A cosmetic composition containing at least one block copolymer having a hard segment and a soft segment, at least one tackifier component, at least one solvent, or solvent mixture, at least one shine enhancing agent, and optionally, at least one colorant, and wherein the at least one hard segment has a Tg value of 50 DEG C. or more and the at least one soft segment has a Tg value of 20 DEG C. or less, and the at least one solvent, or solvent mixture, is capable of solubilizing either the at least one hard segment or the at least one soft segment, or both the hard and the soft segments.

Priority:

Inventor: BUI HY SI [US]; LU SHAOXIANG [US]; PRADIER FRANCOIS [US]; MERCADO RAMON [US]; BLIN XAVIER [FR]


Patent No.: US8557295B2  Issued: 15/Oct/2013

Title: USE OF CELLULAR EXTRACTS FOR SKIN REJUVENATION

Applicant/Assignee: REGENICS AS

Application No.: 13/101445   Filing Date: 05/May/2011

Abstract:

The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts.

Priority: US2009-437100 Applic. Date: 2009-05-07; US2007-801778 Applic. Date: 2007-05-11; US2010-332047P Applic. Date: 2010-05-06; US2008-051931P Applic. Date: 2008-05-09; US2008-120146P Applic. Date: 2008-12-05; US2006-799560P Applic. Date: 2006-05-11

Inventor: GAMMELSAETER RUNHILD [NO]; REMMEREIT JAN [NO]


Patent No.: US8562961B2  Issued: 22/Oct/2013

Title: REFRESHING CREAM FOUNDATION IN GEL FORM

Applicant/Assignee: L'OREAL S.A, L'OREAL

Application No.: 12/825623   Filing Date: 29/Jun/2010

Abstract:

The present invention is directed to a cosmetic composition includes (a) at least one sugar silicone surfactant

(b) at least one polyamine

(c) at least one oil-soluble polar modified polymer

(d) at least one gelling agent

(e) at least one hyperbranched polyol

and (f) water.

Priority: US2009-221255P Applic. Date: 2009-06-29

Inventor: BUI HY SI [US]; KANJI MOHAMED [US]; HALPERN SUSAN [US]


Patent No.: US8562962B2  Issued: 22/Oct/2013

Title: Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation

Applicant/Assignee: MARY KAY, INC, MARY KAY INC

Application No.: 13/619677   Filing Date: 14/Sep/2012

Abstract:

Disclosed is a topical skin composition, and methods for its use, comprising a chemically compatible combination of one or more surfactants and at least one chelating agent, an algae extract, and magnesium ascorbyl phosphate, wherein the composition is formulated for topical application to skin.

Priority: US2009-632554 Applic. Date: 2009-12-07; US2008-202924 Applic. Date: 2008-09-02; US2007-624840 Applic. Date: 2007-01-19; US2002-273649 Applic. Date: 2002-12-12; US1999-357288 Applic. Date: 1999-07-20

Inventor: SCHILTZ JOHN R [US]


Patent No.: US8562984B2  Issued: 22/Oct/2013

Title: Methods of treatment using anti-IL-20 antibodies

Applicant/Assignee: ZYMOGENETICS, INC

Application No.: 13/185368   Filing Date: 18/Jul/2011

Abstract:

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

Priority: US2009-433784 Applic. Date: 2009-04-30; US2008-043046 Applic. Date: 2008-03-05; US2006-458666 Applic. Date: 2006-07-19; US2003-424658 Applic. Date: 2003-04-28; US2000-746359 Applic. Date: 2000-12-22; US2000-213341P Applic. Date: 2000-06-22; US1999-171969P Applic. Date: 1999-12-23

Inventor: THOMPSON PENNY [US]; BLUMBERG HAL [US]; CHANDRASEKHER YASMIN A [US]; NOVAK JULIA E [US]


Patent No.: US8563514B2  Issued: 22/Oct/2013

Title: Peptides and pharmaceutical compositions for treating connective tissue

Applicant/Assignee: METAMOREFIX

Application No.: 12/733137   Filing Date: 14/Aug/2008

Abstract:

Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells to be sequestered. The pharmaceutical composition can be used in the treatment of connective tissue, and can be used as a dermal filler.

Priority: US2007-935490P Applic. Date: 2007-08-15; US2008-006501P Applic. Date: 2008-01-16; WO2008IL01121 Applic. Date: 2008-08-14

Inventor: DAHAN MAZAL [IL]; GORODETSKY RAPHAEL [IL]


Patent No.: US8568704B2  Issued: 29/Oct/2013

Title: Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE, GALDERMA RESEARCH & DEVELOPMENT

Application No.: 12/453968   Filing Date: 28/May/2009

Abstract:

Topically applicable, dermatological/pharmaceutical compositions contain, formulated into a physiologically acceptable medium, benzoyl peroxide, at least one naphthoic acid compound and at least one compound of the polyurethane polymer type or derivatives thereof, wherein the benzoyl peroxide and the at least one naphthoic acid compound are dispersed therein.

Priority: FR20060055138 Applic. Date: 2006-11-28; WO2007FR52412 Applic. Date: 2007-11-28

Inventor: MALLARD CLAIRE [FR]; AT EMMANUELLE [FR]


Patent No.: US8568748B2  Issued: 29/Oct/2013

Title: Pharmaceutical formulation comprising cyclosporin and use thereof

Applicant/Assignee: JAGOTEC AG

Application No.: 10/498656   Filing Date: 14/Dec/2001

Abstract:

The present invention relates to a pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and/or integumentary structures of the skin and/or mucous membranes, including mucous membranes of the digestive tract, uro-genital tract and bronchial system and/or conjunctiva, containing a lipophilic phase in a quantity of 1-10% by weight, a mixture of surfactant and co-surfactant in a quantity of 1-50% by weight, a hydrophilic phase in a quantity of 40-80% by weight and, as active ingredient, cyclosporin and/or derivatives thereof in a concentration of 0.1-20% by weight.

Priority: WO2001EP14749 Applic. Date: 2001-12-14

Inventor: WOHLRAB JOHANNES [DE]; NEUBERT REINHARD [DE]; JAHN KONSTANZE [DE]


Patent No.: US8568752B2  Issued: 29/Oct/2013

Title: TREATMENT AND COMPOSITION FOR ACHIEVING SKIN ANTI-AGING BENEFITS BY CORNEUM PROTEASE ACTIVATION

Applicant/Assignee: MARY KAY, INC, MARY KAY INC

Application No.: 13/852542   Filing Date: 28/Mar/2013

Abstract:

Disclosed is a method of brightening skin or evening out the tone of skin comprising topically applying to skin in need thereof a composition comprising a chemically compatible combination of one or more surfactants and at least one chelating agent, ascorbic acid or a derivative thereof, algae extract, and kelp or sodium sulfite and sodium metabisulfite.

Priority: US201213619677 Applic. Date: 2012-09-14; US2009-632554 Applic. Date: 2009-12-07; US2008-202924 Applic. Date: 2008-09-02; US2007-624840 Applic. Date: 2007-01-19; US2002-273649 Applic. Date: 2002-12-12; US1999-357288 Applic. Date: 1999-07-20

Inventor: SCHULTZ JOHN R [US]


Patent No.: US8569234B2  Issued: 29/Oct/2013

Title: Compositions and methods for including melanogenesis in a subject

Applicant/Assignee: CLINUVEL PHARMACEUTICALS LIMITED

Application No.: 11/664879   Filing Date: 07/Oct/2005

Abstract:

Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.

Priority: US2004-617359P Applic. Date: 2004-10-08; WO2005AU01552 Applic. Date: 2005-10-07

Inventor: KLEINIG MICHAEL JOHN [AU]; KIRBY KENNETH B [US]; PETTERSSON JR BERNO I [US]


Patent No.: US8569243B2  Issued: 29/Oct/2013

Title: Sirtuin 6 activating peptides and cosmetic or pharmaceutical composition containing them

Applicant/Assignee: ISP INVESTMENTS INC, ELC MANAGEMENT LLC

Application No.: 13/166836   Filing Date: 23/Jun/2011

Abstract:

The present invention relates to sirtuin 6 activating peptides derived from highly conserved regions of human Sirtuin (SIRT) proteins, and to a cosmetic or pharmaceutical composition comprising at least one sirtuin 6 activating peptide in a physiologically acceptable medium. The invention further relates to the utilization of a cosmetic composition to prevent and/or repair Deoxyribonucleic acid (DNA) degradation, improve telomere maintenance and reduce cellular senescence. The invention also applies to a cosmetic treatment process intended to prevent and/or treat the cutaneous signs of aging and photo aging.

Priority: FR20100002698 Applic. Date: 2010-06-29

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]; IMBERT ISABELLE [FR]; PERNODET NADINE [US]


Patent No.: US8574558B2  Issued: 05/Nov/2013

Title: UV-CURABLE NAIL COATING FORMULATIONS BASED ON RENEWABLE POLYOLS

Applicant/Assignee: MYCONE DENTAL SUPPLY CO., INC

Application No.: 13/012066   Filing Date: 24/Jan/2011

Abstract:

A photopolymerizable composition for forming a cosmetic coating for natural and artificial nails of humans and animals comprising a photoinitiator and a (meth)acrylate monomer prepared by reacting a core polyol derived or functionalized from a renewable resource with an a (meth)acrylate monomer and coatings formed from such compositions under UV or other radiation.

Priority: US2010-298015P Applic. Date: 2010-01-25

Inventor: STEFFIER LAWRENCE W [US]


Patent No.: US8575089B2  Issued: 05/Nov/2013

Title: COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION

Applicant/Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE

Application No.: 13/390888   Filing Date: 17/Aug/2010

Abstract:

The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating the inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury.

Priority: KR20090075881 Applic. Date: 2009-08-17; WO2010KR05420 Applic. Date: 2010-08-17

Inventor: SON YOUNG SOOK [KR]; HONG HYUN SOOK [KR]; KIM DO YEON [KR]; LEE EUN KYUNG [KW]


Patent No.: US8580741B2  Issued: 12/Nov/2013

Title: COSMETIC COMPOSITIONS FOR SKIN-TIGHTENING AND METHOD OF SKIN-TIGHTENING USING THE SAME

Applicant/Assignee: STC NARA CO., LTD

Application No.: 12/522401   Filing Date: 11/Jan/2007

Abstract:

The present invention relates to a skin-tightening cosmetic composition and a method of applying the same, and more specifically, to a cosmetic composition a method of applying the same that includes a hydrolyzed plant protein and glycoprotein. The cosmetic composition includes a hydrolyzed plant protein and glycoprotein in an optimal amount, thereby causing the occurrence of an immediate contraction effect and a long-lasting contracting effect, and achieving skin improvements such as skin moisturizing and induction of synthesizing collagen and elastine in use of the composition over a long period of time.

Priority: KR20070001883 Applic. Date: 2007-01-08; WO2007KR00199 Applic. Date: 2007-01-11

Inventor: LEE KYE-HO [KR]; CHUNG SUNG-HO [KR]; SONG JI-HOON [KR]; YOON JIN-SUNG [KR]; LEE JI-HYUN [KR]; JUNG MOON-JU [KR]; KIM JONG-HWAN [KR]


Patent No.: US8580742B2  Issued: 12/Nov/2013

Title: Topical Glutathione Formulations For Menopausal Skin

Applicant/Assignee: N.V. PERRICONE LLC

Application No.: 12/718706   Filing Date: 05/Mar/2010

Abstract:

Topical compositions to address menopausal skin conditions comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for addressing menopausal skin conditions comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C12-C24 group, preferably an unsaturated C16-C24 group, most preferably an unsaturated C18 group. In particularly preferred embodiments, the acyl group is a linoleoyl group.

Priority:

Inventor: PERRICONE NICHOLAS V [US]


Patent No.: US8586540B2  Issued: 19/Nov/2013

Title: Composition for Improving Skin Conditions Using Fetal Mesenchymal Stem Cells from Amniotic Fluid

Applicant/Assignee: STEMMEDIENCE CO., LTD

Application No.: 13/257623   Filing Date: 19/Mar/2010

Abstract:

The present invention relates to a culture medium for the fetus-derived mesenchymal stem cells in amniotic fluid. More particularly, the present invention relates to a composition for improving skin conditions, comprising the culture medium of fetus-derived mesenchymal stem cells in amniotic fluid as an active ingredient, in which the skin conditions to be improved include whitening, wrinkles, skin damages caused by UV rays or skin lifting. Further, the present invention relates to a method for preparing the composition, comprising the steps of culturing the fetus-derived mesenchymal stem cells in amniotic fluid

and collecting the culture medium.

Priority: KR20090024055 Applic. Date: 2009-03-20; WO2010KR01729 Applic. Date: 2010-03-19

Inventor: YOU SEUNGKWON [KR]; YOON BYUNG SUN [KR]; MOON JAI-HEE [KR]; JUN EUN KYOUNG [KR]; KIM JONGGUN [KR]; JUNG HYE-YOUN [KR]; LEE JUNG HAN [KR]; PARK EULSOON [KR]; MAENG ISAAC [KR]; KIM JUN SUNG [KR]; LEE JANG HO [KR]; LEE HWANG HEUI [KR]; LEE JONG WON [KR]; CHO KYOUNG SHIK [KR]


Patent No.: US8591875B2  Issued: 26/Nov/2013

Title: Biodegradable Phosphoester Polyamines

Applicant/Assignee: COVIDIEN LP

Application No.: 12/160929   Filing Date: 22/Feb/2007

Abstract:

Novel biodegradable phosphoester polyamines are disclosed. The biodegradable phosphoester polyamines may be utilized as cross-linkers for sprayable compositions which may be used as tissue adhesives or sealants.

Priority: US2006-775749P Applic. Date: 2006-02-22; WO2007US04477 Applic. Date: 2007-02-22

Inventor: BELCHEVA NADYA [US]; HADBA AHMAD R [US]


Patent No.: US8597628B2  Issued: 03/Dec/2013

Title: COSMETIC WATER-IN-OIL EMULSION COMPOSITIONS

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: 12/920538   Filing Date: 10/Mar/2009

Abstract:

Cosmetic water-in-oil emulsion compositions containing solid particles and high concentrations of a specific silicone elastomer and including high content of polysilicon-11, solid particles providing at least one optical effect, and at least one silicon emulsifier are suitable for use for making up the face and/or lips or eyelids, preferably as foundations. They may also be used to as a base for make-up, or as a skin care cream to be applied on the body or face. These compositions result in a product that enhances the overall appearance of the skin by providing strong blurring effects to give anti-wrinkle/fine line effects, skin smoothness, and radiance while unifying color complexion. These compositions also have unique sensorial properties.

Priority: US2008-035095P Applic. Date: 2008-03-10; WO2009EP52791 Applic. Date: 2009-03-10

Inventor: ROMAINE CAROLYN [US]


Patent No.: US8597717B2  Issued: 03/Dec/2013

Title: Oriented Collagen Gel

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Application No.: 13/671671   Filing Date: 08/Nov/2012

Abstract:

Techniques for the production of flow-oriented collagen gels using hydrodynamics to influence the assembly of collagen fibers. Highly concentrated monomeric solutions of collagen are subjected to shear and extensional flow as they are drawn onto a substrate to induce fibrillogenesis under a high Ph buffer. The produced gel captures the flow induced ordering of molecular collagen upon fibril formation. The depositing or the induction of fibrillogenosis occurs without the application of a magnetic field to the concentration of collagen. These highly oriented 3D scaffolds are capable inducing contact guidance and guiding mammalian cell growth. The collagen fibers mimic the construction of in vivo fibers with the characteristic D-periodicity and the integrin receptors on the fibroblasts respond to this organization.

The industrial applications of three-dimensional collagen gels as a biomaterial are widespread from drug delivery to burn repair or tissue engineering system.

Priority: US2010-660702 Applic. Date: 2010-03-02; US2009-209239P Applic. Date: 2009-03-04

Inventor: FULLER GERALD G [US]; KIRKWOOD JOHN E [US]


Patent No.: US8598122B2  Issued: 03/Dec/2013

Title: ANTAGONISTIC PEPTIDES FOR FRIZZLED-1 AND FRIZZLED-2

Applicant/Assignee: ACADEMISCH ZIEKENHUIS MAASTRICHT, UNIVERSITEIT MAASTRICHT

Application No.: 13/138537   Filing Date: 18/Feb/2010

Abstract:

The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled-2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.

Priority: EP20090154475 Applic. Date: 2009-03-05; WO2010EP52058 Applic. Date: 2010-02-18

Inventor: BLANKESTEIJN WESSEL MATTHIJS [NL]; LAEREMANS HILDE [NL]; HACKENG TILMAN MATHIAS [NL]


Patent No.: US8598124B2  Issued: 03/Dec/2013

Title: PEPTIDES DERIVED FROM HMG-COA REDUCTASE AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/141358   Filing Date: 23/Dec/2009

Abstract:

The present invention relates to peptides derived from human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Lys-X2-(AA)p-R2, And of sequence SEQ ID No. 1 to SEQ ID No. 10. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Priority: FR20080007364 Applic. Date: 2008-12-23; WO2009FR01476 Applic. Date: 2009-12-23

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Patent No.: US8603451B2  Issued: 10/Dec/2013

Title: Adhesive Compositions for Medical Use: Single Additive as Both the Thickening Agent and the Accelerator

Applicant/Assignee: ADHEZION BIOMEDICAL, LLC

Application No.: 13/477172   Filing Date: 22/May/2012

Abstract:

The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field.

Priority: US2008-214794 Applic. Date: 2008-06-20

Inventor: ZHANG SHENG [US]; RUIZ RAFAEL [US]


Patent No.: US8603973B2  Issued: 10/Dec/2013

Title: Skincare Composition Comprising HSA Fusion Protein, Preparation Method And Uses Thereof

Applicant/Assignee: TIANJIN SINOBIOTECH LTD, FORTUNEROCK, INC. USA

Application No.: 12/529981   Filing Date: 24/Sep/2008

Abstract:

The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.

Priority: CN2007159770 Applic. Date: 2007-09-25; US2008-203116 Applic. Date: 2008-09-02; US2007-825686 Applic. Date: 2007-07-08; US2003-609346 Applic. Date: 2003-06-26; US2004-851666 Applic. Date: 2004-05-24; US2002-392948P Applic. Date: 2002-07-01; US2003-483948P Applic. Date: 2003-06-30; WO2008CN72485 Applic. Date: 2008-09-24

Inventor: FU YAN [US]; YU ZAILIN [US]


Patent No.: US8609618B2  Issued: 17/Dec/2013

Title: Topical Palmitoyl Glutathione Formulations

Applicant/Assignee: N.V. PERRICONE LLC

Application No.: 13/072277   Filing Date: 25/Mar/2011

Abstract:

A topical composition for application to aging skin, comprising an effective amount of S-acyl glutathione derivative of formula (I) wherein R1 consists of an unsaturated or saturated C16 group and R2 is a hydrogen, aliphatic or aromatic acyl group

and a dermatologically acceptable carrier. Preferred compositions comprise about 1.0% to about 3.0% by weight of S-palmitoyl glutathione.

Priority:

Inventor: PERRICONE NICHOLAS V [US]